Condition: Multiple Sclerosis · Sponsor: Biogen
The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and, ii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries). The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).
This description comes directly from the study's public registry record.
US Biogen Clinical Trial Center · 866-633-4636 · clinicaltrials@biogen.com
Global Biogen Clinical Trial Center · clinicaltrials@biogen.com
Always discuss trial participation with your own doctor first.
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| IQVIA US Office | Durham, North Carolina, United States | Recruiting |
| Austin Hospital | Heidelberg, Australia | Recruiting |
| Katholisches Klinikum Bochum | Bochum, North Rhine-Westphalia, Germany | Recruiting |
| St Vincent's University Hospital | Dublin, Ireland | Recruiting |
| Hospital Universitario Ramon y Cajal | Madrid, Spain | Recruiting |
| Inselspital | Bern, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05658497